Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Lower Oncogenic Potential of Human Mesenchymal Stem Cells Derived from Cord Blood Compared to Induced Pluripotent Stem Cells.

Tytuł :
Lower Oncogenic Potential of Human Mesenchymal Stem Cells Derived from Cord Blood Compared to Induced Pluripotent Stem Cells.
Autorzy :
Foroutan T; Department of Animal Biology, Faculty of Biological Sciences, Kharazmi University.
Najmi M; Department of Cell Biology, Faculty of Sciences and New Technologies, Pharmaceutical Sciences Branch of Islamic Azad University.
Kazemi N; Department of Cell Biology, Faculty of Sciences and New Technologies, Pharmaceutical Sciences Branch of Islamic Azad University.
Hasanlou M; Department of Molecular Genetic, Faculty of Biological Sciences, Tarbiat Modares University.
Pedram A; Department of Animal Biology, Faculty of Biological Sciences, Kharazmi University.
Pokaż więcej
Źródło :
International journal of organ transplantation medicine [Int J Organ Transplant Med] 2015; Vol. 6 (3), pp. 99-104.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Original Publication: Shiraz : Avicenna Organ Transplantation Institute
References :
Stem Cells. 2010 Feb;28(2):221-8. (PMID: 20014278)
Genes Dev. 1993 Apr;7(4):671-82. (PMID: 8458579)
Genes Dev. 2005 May 15;19(10):1129-55. (PMID: 15905405)
Circulation. 2006 Jul 4;114(1 Suppl):I114-9. (PMID: 16820559)
N Engl J Med. 2004 Nov 25;351(22):2276-85. (PMID: 15564544)
Stem Cells Dev. 2008 Dec;17(6):1053-63. (PMID: 18597617)
Biores Open Access. 2013 Jun;2(3):179-85. (PMID: 23741628)
Cancer Res. 2008 Jun 1;68(11):4229-38. (PMID: 18519682)
Stem Cells. 2008 Dec;26(12):3068-74. (PMID: 18787205)
Exp Hematol. 2005 Nov;33(11):1402-16. (PMID: 16263424)
Nature. 2007 Jul 19;448(7151):313-7. (PMID: 17554338)
Cell Stem Cell. 2008 Sep 11;3(3):301-13. (PMID: 18786417)
FASEB J. 2003 Sep;17(12):1730-2. (PMID: 12958191)
Ageing Res Rev. 2009 Apr;8(2):94-112. (PMID: 19114129)
J Cell Biochem. 2009 Apr 15;106(6):984-91. (PMID: 19229871)
Cytotherapy. 2009;11(4):377-91. (PMID: 19568970)
Mol Cell Biol. 2006 Oct;26(20):7772-82. (PMID: 16954384)
Cytotherapy. 2005;7(5):393-5. (PMID: 16236628)
Stem Cells Dev. 2012 Jan;21(1):1-6. (PMID: 21780911)
Differentiation. 2009 Nov;78(4):232-40. (PMID: 19664871)
Nat Rev Mol Cell Biol. 2007 Sep;8(9):703-13. (PMID: 17717515)
Cell. 2006 Aug 25;126(4):663-76. (PMID: 16904174)
Nat Rev Immunol. 2008 Sep;8(9):726-36. (PMID: 19172693)
J Cell Physiol. 2008 Feb;214(2):413-21. (PMID: 17654479)
Stem Cells Dev. 2010 Apr;19(4):491-502. (PMID: 19635009)
PLoS One. 2009 Jun 09;4(6):e5846. (PMID: 19513108)
Stem Cells. 2005 Sep;23 (8):1035-43. (PMID: 15983365)
Int J Clin Rheumtol. 2009 Feb 1;4(1):57-66. (PMID: 20490372)
Cell Stem Cell. 2008 Nov 6;3(5):568-74. (PMID: 18983970)
Stem Cells. 2009 Dec;27(12):2969-78. (PMID: 19816951)
Leukemia. 2007 May;21(5):860-7. (PMID: 17344915)
Science. 2000 Feb 25;287(5457):1439-41. (PMID: 10688784)
Nat Biotechnol. 2008 Nov;26(11):1269-75. (PMID: 18849973)
Carcinogenesis. 2005 Feb;26(2):495-502. (PMID: 15513931)
Nat Protoc. 2011 Mar;6(3):346-58. (PMID: 21372815)
Blood. 2004 Apr 15;103(8):2956-64. (PMID: 15070671)
Calcif Tissue Int. 1995 Feb;56(2):123-9. (PMID: 7736320)
J Surg Res. 2012 Nov;178(1):63-70. (PMID: 22482751)
Stem Cells. 2001;19(3):193-204. (PMID: 11359944)
Stem Cells. 2007 Jul;25(7):1675-80. (PMID: 17379765)
Contributed Indexing :
Keywords: Cord blood; Mesenchymal stem cells; OCT4; Sox2; c-Myc; Nanog; lin28
Entry Date(s) :
Date Created: 20150826 Date Completed: 20150826 Latest Revision: 20201001
Update Code :
20210914
PubMed Central ID :
PMC4545303
PMID :
26306155
Czasopismo naukowe
Background: In regenerative medicine, use of each of the mesenchymal stem cells derived from bone marrow, cord blood, and adipose tissue, has several cons and pros. Mesenchymal stem cells derived from cord blood have been considered the best source for precursor transplantation. Direct reprogramming of a somatic cell into induced pluripotent stem cells by over-expression of 6 transcription factors Oct4, Sox2, Klf4, lin28, Nanog, and c-Myc has great potential for regenerative medicine, eliminating the ethical issues of embryonic stem cells and the rejection problems of using non-autologous cells.
Objective: To compare reprogramming and pluripotent markers OCT4, Sox-2, c-Myc, Klf4, Nanog, and lin28 in mesenchymal stem cells derived from cord blood and induced pluripotent stem cells.
Methods: We analyzed the expression level of OCT4, Sox-2, c-Myc, Klf4, Nanog and lin28 genes in human mesenchymal stem cells derived from cord blood and induced pluripotent stem cells by cell culture and RT-PCR.
Results: The expression level of pluripotent genes OCT4 and Sox-2, Nanog and lin28 in mesenchymal stem cells derived from cord blood were significantly higher than those in induced pluripotent stem cells. In contrast to OCT-4A and Sox-2, Nanog and lin28, the expression level of oncogenic factors c-Myc and Klf4 were significantly higher in induced pluripotent stem cells than in mesenchymal stem cells derived from cord blood.
Conclusion: It could be concluded that mesenchymal stem cells derived from human cord blood have lower oncogenic potential compared to induced pluripotent stem cells.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies